A PHASE II STUDY OF MK-2206 IN PATIENTS WITH PROGRESSIVE, RECURRENT/METASTATIC ADENOID CYSTIC CARCINOMA

Trial Profile

A PHASE II STUDY OF MK-2206 IN PATIENTS WITH PROGRESSIVE, RECURRENT/METASTATIC ADENOID CYSTIC CARCINOMA

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs MK 2206 (Primary)
  • Indications Adenocarcinoma; Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2015 Results in 16 patients presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 Primary endpoint has not been met. (Confirmed Response Rate (Complete Response + Partial Response) According to RECIST Version 1.1)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top